Skip to content

Advertisement

Volume 11 Supplement 1

Challenges in malaria research

  • Oral presentation
  • Open Access

Overcoming the affordability barrier for effective and high quality life saving malaria medicines in the private sector in rural Uganda: the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study

  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 3,
  • 3,
  • 3,
  • 3,
  • 3,
  • 3,
  • 4,
  • 4,
  • 5,
  • 5,
  • 5,
  • 5,
  • 6,
  • 6,
  • 7,
  • 7,
  • 7,
  • 8,
  • 9,
  • 1 and
  • 1
Malaria Journal201211 (Suppl 1) :O16

https://doi.org/10.1186/1475-2875-11-S1-O16

  • Published:

Keywords

  • Malaria
  • Private Sector
  • Malaria Treatment
  • Exit Survey
  • Intervention District

Background

Artemisinin-based combination therapies (ACTs), the treatment of choice for non-complicated falciparum malaria, are unaffordable and inaccessible in the private sector, yet the private sector is the first port of call for malaria treatment across most of rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to effective malaria treatment could be improved through the provision of highly subsidized ACTs in the private sector.

Methods

Four intervention districts (Pallisa, Budaka, Kamuli and Kaliro) were purposefully selected to receive branded subsidized medicines-”ACT with a leaf”, while the fifth district (Soroti) acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at all licensed private drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention’s impact on: ACT uptake; access to ACTs within 24 hours of symptom-onset; and displacement of sub-optimal antimalarials.

Results

At baseline, the market share of ACTs was < 1%. However, at evaluation, “ACT with a leaf” had a market share of 69% in the interventions districts. Access to ACTs within 24 hours of symptom onset rose from 0.8% at baseline to 26.2% (95% CI: 23.2 - 29.2%) at evaluation in the intervention districts. In the control district it modestly rose from 1.8% to 5.6% (95% CI: 4.0 - 7.3%). The odds of accessing ACTs within 24 hours in the intervention compared to the control districts was 0.46 (95% CI: 0.08 - 2.68, p = 0.4), at baseline and significantly increased to 6.11 (95% CI: 4.32 - 8.62, p < 0.0001) at evaluation. Children less than 5 years-old had “ACT with a leaf” purchased for them more often than those aged above 5 years. There was no evidence of price gouging.

Conclusions

Our data demonstrate that a supply-side antimalarial subsidy coupled with an intensive communications campaign significantly increased the uptake of ACTs in the private sector in Uganda.

Authors’ Affiliations

(1)
Medicines for Malaria Venture-MMV, Switzerland
(2)
Malaria Public Health &Epidemiology Cluster, University of Oxford-KEMRI-Wellcome Trust Research Programme and Worldwide Antimalarial Resistance Network-WWARN, Kenya
(3)
Uganda Ministry of Health-Ug-MoH, Uganda
(4)
Uganda National Drug Authority-NDA, Uganda
(5)
Programme for Accessible Health Communication and Education-PACE, Uganda
(6)
Malaria Consortium-MC, Uganda
(7)
Surgipharm Pharmaceuticals, Uganda
(8)
l+Solutions, Uganda
(9)
Management Sciences for Health-MSH, Uganda

Copyright

© Talisuna et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement